PDCD1 and hepatocellular carcinoma: Recently, the combination of anti-PD-1 antibody atezolizumab and anti-VEGF antibody bevacizumab was shown to improve recurrence-free survival in patients with resected or ablated high-risk HCC in a phase 3 trial [9].